Page last updated: 2024-12-08

ly 293111

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY 293111: a leukotriene B4 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID177941
CHEMBL ID329123
CHEBI ID187612
SCHEMBL ID1649516
MeSH IDM0247963

Synonyms (47)

Synonym
ly-293111
vml 295
CHEMBL329123 ,
ly-193111
bdbm50029450
2-{3-[3-(5-ethyl-4''-fluoro-2-hydroxy-biphenyl-4-yloxy)-propoxy]-2-propyl-phenoxy}-benzoic acid
etalocib sodium
PDSP2_001221
PDSP1_001237
etalocib (usan)
D04074
161172-51-6
etalocib
ly293111
L001468
2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid
2-[3-[3-[2-ethyl-4-(4-luorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid
CHEBI:187612
152608-41-8
thy6riw44r ,
unii-thy6riw44r
ly 293111
vml295
2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxybiphenyl-4-yl)oxy)propoxy)-2-propylphenoxy)benzoic acid
benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-biphenyl)-4-yl)oxy)propoxy)-2-propylphenoxy)-
etalocib [usan:inn]
gtpl2948
etalocib [inn]
etalocib [who-dd]
etalocib [usan]
SCHEMBL1649516
YFIZRWPXUYFCSN-UHFFFAOYSA-N
2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid
2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy-[1,1'-biphenyl]-4-yl)oxy)propoxy)-2-propylphenoxy)benzoic acid ,
DTXSID70167073
J-009797
DB12850
Q5402392
ly 293111; vml 295
HY-13628
CS-0007495
BS-44942
EX-A4533
benzoic acid, 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]-
vml295ly293111
E85703
AKOS040745050

Research Excerpts

Overview

LY 293111 is an oral agent known to be a leukotriene B4 antagonist, a 5-lipoxygenase inhibitor and a peroxisome proliferator-activated receptor (PPAR)-gamma agonist with cytotoxic properties.

ExcerptReferenceRelevance
"LY 293111 is an oral agent known to be a leukotriene B4 antagonist, a 5-lipoxygenase inhibitor and a peroxisome proliferator-activated receptor (PPAR)-gamma agonist with cytotoxic properties in cell lines."( Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.
Budman, DR; Calabro, A, 2004
)
1.25

Actions

ExcerptReferenceRelevance
"LY 293111 displays global synergy with the active metabolite of irinotecan, SN-38, in the majority of cell lines, synergistic to additive effects with gemcitabine in bladder cancer cell lines, and synergism with 5'-DFUR (the active metabolite of capecitabine) in two breast cancer and one sarcoma cell line."( Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.
Budman, DR; Calabro, A, 2004
)
1.25

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells."( Effect of LY293111 in combination with gemcitabine in colonic cancer.
Adrian, TE; Ding, XZ; Hennig, R; Jovanovic, BD; Tong, WG; Witt, RC, 2004
)
0.32
" Antineoplastic activity of LY293111 has been identified in preclinical models both alone and in combination with chemotherapy agents including irinotecan."( A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A, 2007
)
0.34
"Dose limiting toxicity (DLT) of grade 3 diarrhea was seen in two patients with doses of irinotecan 300 mg/m(2) IV every 21-days in combination with LY293111 300 mg BID."( A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A, 2007
)
0.34
"The recommended phase II dose of LY293111 is 600 mg orally BID in combination with irinotecan 250 mg/m(2) IV every 21-days."( A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
"The dose-response relationship between aerosolized leukotriene B4 (LTB4 and pulmonary neutrohilia was examined in a group of five rhesus monkeys."( The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys.
Abbott, DL; Allen, DL; Hoffman, WP; Leiter, PA; Marder, P; Matchett, MR; Wolff, RK, 1996
)
0.29
" The inhibitory effect was maximum at the end of dosing and had disappeared by day 14."( Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist.
Cerimele, BJ; Froelich, LL; Lucas, RA; Marder, P; Petersen, BH; Spaethe, SM; Tanner, T, 1996
)
0.29
" It has previously been shown in human volunteers that VML 295 at a dosage of 48 mg twice daily inhibits the ex vivo leukotriene B(4) (LTB(4))-induced upregulation of CD11b on peripheral blood neutrophils."( Pharmacological effects of a specific leukotriene B(4) receptor antagonist (VML 295) on blood leukocytes, cutaneous inflammation and epidermal proliferation.
Andriessen, MP; de Bakker, ES; Parker, GL; Seegers, BA; van de Kerkhof, PC; van Erp, PE; van Hooijdonk, CA; van Vlijmen-Willems, IM,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene B4 receptor 1Homo sapiens (human)IC50 (µMol)0.00330.00080.30913.2500AID91333
Leukotriene B4 receptor 1Homo sapiens (human)Ki0.02100.00010.51267.0000AID102636; AID102640
Leukotriene B4 receptor 2Homo sapiens (human)IC50 (µMol)0.00330.00200.53022.9000AID91333
Leukotriene B4 receptor 2Homo sapiens (human)Ki0.01700.00190.12800.5240AID102636
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
muscle contractionLeukotriene B4 receptor 1Homo sapiens (human)
inflammatory responseLeukotriene B4 receptor 1Homo sapiens (human)
immune responseLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
chemotaxisLeukotriene B4 receptor 2Homo sapiens (human)
negative regulation of adenylate cyclase activityLeukotriene B4 receptor 2Homo sapiens (human)
keratinocyte migrationLeukotriene B4 receptor 2Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 2Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nucleotide bindingLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 2Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
nucleoplasmLeukotriene B4 receptor 2Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 2Homo sapiens (human)
membraneLeukotriene B4 receptor 2Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1346072Human BLT1 receptor (Leukotriene receptors)1999The Journal of pharmacology and experimental therapeutics, Jan, Volume: 288, Issue:1
Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
AID102636Binding affinity towards human LTB4 receptor measured as inhibition of binding of [3H]LTB4 to isolated human neutrophils1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.
AID91333Inhibition of LTB4 induced expression of human neutrophil integrin CD11b/CD18.1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.
AID91005Compound was tested in vitro inhibitory activity against human neutrophil CD11b/CD18. 1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID89255Compound was tested in vitro inhibitory activity against LTB4 induced Ca mobilization1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID76801Compound was tested in vivo inhibitory activity against LTB4 induced bronchoconstriction (intravenous)1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID76802Compound was tested in vivo inhibitory activity against LTB4 induced bronchoconstriction (orally)1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID102297Binding affinity towards Leukotriene B4 receptor guinea pig lung membrane using [3H]LTB4 as radioligand1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.
AID102640Compound was tested for inhibitory activity against human neutrophil LTB4 receptor binding1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (30.56)18.2507
2000's19 (52.78)29.6817
2010's6 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.49 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (23.68%)5.53%
Reviews3 (7.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (68.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]